Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: A hospital-based retrospective cohort study
Mook, S., Schmidt, M.K., Rutgers, E.J., van de Velde, A.O., Visser, O., Rutgers, S.M., Armstrong, N., van't Veer, L.J. and Ravdin, P.M. (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: A hospital-based retrospective cohort study. The Lancet Oncology, 10 (11). pp. 1070-1076.
*Subscription may be required
Adjuvant! is a web-based program that calculates individualised 10-year survival probabilities and predicted benefit of adjuvant systemic therapy. The Adjuvant! model has not been validated in any large European series. The aim of our study was to validate Adjuvant! in Dutch patients, investigating both its calibration and discriminatory accuracy.
Patients who were at least partly treated at the Netherlands Cancer Institute for breast cancer between 1987 and 1998 were included if they met the following criteria: tumour size T1 (≤2 cm), T2 (2–5 cm), or T3 (>5 cm), invasive breast carcinoma, with information about involvement of axillary lymph nodes available, no distant metastases, primary surgery, axillary staging, and radiotherapy according to national guidelines. Clinicopathological characteristics and adjuvant treatment data were retrieved from hospital records and medical registries and were entered into the Adjuvant! (version 8.0) batch processor with blinding to outcome. Endpoints were overall survival and the proportion of patients that did not die from breast cancer (breast-cancer-specific survival [BCSS]).
5380 patients were included with median follow-up of 11•7 years (range 0•03–21•8). The 10-year observed overall survival (69•0%) and BCSS (78•6%) and Adjuvant! predicted overall survival (69•1%) and BCSS (77•8%) were not statistically different (p=0•87 and p=0•18, respectively). Moreover, differences between predicted and observed outcomes were within 2% for most relevant clinicopathological subgroups. In patients younger than 40 years, Adjuvant! overestimated overall survival by 4•2% (p=0•04) and BCSS by 4•7% (p=0•01). The concordance index, which indicates discriminatory accuracy at the individual level, was 0•71 for BCSS in the entire cohort.
Adjuvant! accurately predicted 10-year outcomes in this large-scale Dutch validation study and is of use for adjuvant treatment decision making, although the results may be less reliable in some subgroups.
Dutch National Genomics Initiative-Cancer Genomics Center, Dutch Cancer Society-KWF.
|Publication Type:||Journal Article|
|Copyright:||© 2009 Elsevier Ltd|
|Item Control Page|